Results 41 to 50 of about 5,019 (231)

Membrane‐Bound Multimodal Plasmonic Transducers for Noninvasive, In Situ Monitoring and Control of CAR T Cells Against Heterogeneous Solid Tumors

Advanced Materials, EarlyView.
Membrane‐bound multimodal transducers enable longitudinal ultrasound‐guided photoacoustic monitoring and in situ thermal control of CAR T cells in heterogeneous solid tumors. Imaging correlates T cell trafficking with tumor response, distinguishing responders from nonresponders.
Myeongsoo Kim, Ali Zamat, Melissa Cadena, Chloé Thiveaud, Riya Sen, Jeungyoon Lee, Elif Kulaksizoglu, S. Abbey Oliver, Don VanderLaan, Sydney Fábrega, Zizhen Zha, Kelsey P. Kubelick, Jinhwan Kim, Gabriel A. Kwong, Stanislav Y. Emelianov   +14 more
wiley   +1 more source

Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies

Journal of Hematology & Oncology, 2021
Harnessing the power of immune cells, especially T cells, to enhance anti-tumor activities has become a promising strategy in clinical management of hematologic malignancies.
Zheng Tian, Ming Liu, Ya Zhang, Xin Wang
doaj   +1 more source

Endobody: Genetically Encodable Nanobody‐CPP Chimeras for Degradation of Membrane and Extracellular Proteins

Advanced Science, EarlyView.
We introduced genetically encodable, receptor‐independent nanobody‐CPP chimeras, termed endobodies, as robust and modular membrane protein degraders. Additionally, proteasome‐targeting domain (PTD)‐tethered endobody demonstrates further enhanced degradation potency.
Chengjian Zhou, Huiping He, Simin Xia, Xi Chen   +3 more
wiley   +1 more source

Synapse topology and downmodulation events determine the functional outcome of anti-CD19 T cell-redirecting strategies

OncoImmunology, 2022
Cancer immunotherapy strategies based on the endogenous secretion of T cell-redirecting bispecific antibodies by engineered T lymphocytes (STAb-T) are emerging as alternative or complementary approaches to those based on chimeric antigen receptors (CAR-T)
Ángel Ramírez-Fernández, Óscar Aguilar-Sopeña, Laura Díez-Alonso, Alejandro Segura-Tudela, Carmen Domínguez-Alonso, Pedro Roda-Navarro, Luis Álvarez-Vallina, Belén Blanco   +7 more
doaj   +1 more source

Cell‐Selective Delivery of RIBOTACs via an Anti‐EGFR Nanobody for Pancreatic Cancer Treatment

Advanced Science, EarlyView.
This study introduces an innovative strategy for the tumor‐selective catalytic degradation of oncogenic non‐coding RNA by interfacing a ribonuclease‐recruiting small molecule (RIBOTAC) with an EGFR‐targeting nanobody via a CTSB (Cathepsin B)‐responsive linker.
Tianli Luo, Yijuan Wang, Dengwang Chen, Yinghan Zhang, Yi Shuai, Hualiang Yao, Tao Jiang, Hang Jiang, Ming Zhong, Xiangeng Wang, Ziwei Wang, Chenchen Xu, Ajay Goel, Hoi Tang MA, Feng Gao, Xin Wang   +15 more
wiley   +1 more source

mRNA-engineered T lymphocytes secreting bispecific T cell engagers with therapeutic potential in solid tumors

Frontiers in Immunology
BackgroundIn the last decade, chimeric antigen receptor (CAR)-modified T cells have revolutionized the treatment of hematologic malignancies. However, antitumor responses in solid tumors remain poor, and the difficulty in finding truly tumor-specific ...
Ivana Zagorac, Ivana Zagorac, Ivana Zagorac, Ángel Ramírez-Fernández, Ángel Ramírez-Fernández, Antonio Tapia-Galisteo, Antonio Tapia-Galisteo, Antonio Tapia-Galisteo, Laura Rubio-Pérez, Laura Rubio-Pérez, Laura Rubio-Pérez, Marina Gómez-Rosel, Marina Gómez-Rosel, Marina Gómez-Rosel, Montserrat Grau, José Luis Rodríguez-Peralto, José Luis Rodríguez-Peralto, José Luis Rodríguez-Peralto, José Luis Rodríguez-Peralto, Luis Álvarez-Vallina, Luis Álvarez-Vallina, Luis Álvarez-Vallina, Luis Álvarez-Vallina, Belén Blanco, Belén Blanco, Belén Blanco, Belén Blanco   +26 more
doaj   +1 more source

Trispecific T-cell engagers for dual tumor-targeting of colorectal cancer

OncoImmunology, 2022
Retargeting of T lymphocytes toward cancer cells by bispecific antibodies has demonstrated its therapeutic potential, with one such antibody approved for the treatment of acute lymphoblastic leukemia (blinatumomab) and several other in clinical trials ...
Antonio Tapia-Galisteo, Íñigo Sánchez Rodríguez, Oscar Aguilar-Sopeña, Seandean Lykke Harwood, Javier Narbona, Mariola Ferreras Gutierrez, Rocío Navarro, Laura Martín-García, Cesáreo Corbacho, Marta Compte, Javier Lacadena, Francisco J. Blanco, Patrick Chames, Pedro Roda-Navarro, Luis Álvarez-Vallina, Laura Sanz   +15 more
doaj   +1 more source

The Role of Bispecific Antibodies in Non-Hodgkin’s Lymphoma: From Structure to Prospective Clinical Use

Antibodies, 2022
Bispecific antibodies (bsAbs) are molecules that simultaneously bind two different antigens (Ags). bsAbs represent a very active field in tumor immunotherapy with more than one hundred molecules currently being tested.
Rita Tavarozzi, Enrica Manzato
doaj   +1 more source

SOX5 Orchestrates Malignant Evolution via Promoter‐Centric Chromatin Remodeling in MYC‐Driven B‐Cell Lymphoma

Advanced Science, EarlyView.
In MYC‐enforced B‐cell lymphoma, SOX5 occupies promoter‐proximal regulatory regions and is associated with reduced chromatin accessibility at the PCNP locus. PCNP repression promotes proliferative remodeling by limiting apoptosis and cell‐cycle restraint.
Yiyou Mao, Zhenyuan Jia, Xiao‐Qin Mu, Ruilin Wang, Jianli Ma, Qingyuan Zhang, Yuwei Deng   +6 more
wiley   +1 more source

Nanobody-based trispecific T cell engager (Nb-TriTE) enhances therapeutic efficacy by overcoming tumor-mediated immunosuppression

Journal of Hematology & Oncology, 2023
Background T cell engagers (TCEs) have been established as an emerging modality for hematologic malignancies, but solid tumors remain refractory. However, the upregulation of programmed cell death 1 (PD-1) is correlated with T cell dysfunction that ...
Ziqiang Ding, Shuyang Sun, Xuan Wang, Xiaomei Yang, Wei Shi, Xianing Huang, Shenxia Xie, Fengzhen Mo, Xiaoqiong Hou, Aiqun Liu, Xiaobing Jiang, Zhuoran Tang, Xiaoling Lu   +12 more
doaj   +1 more source